Modest interest in Human Safety!?

We have previously highlighted that most European venture capital funded therapeutic companies are acquired after receiving less than EUR 45M in venture capital funding.

It also appears that companies are acquired either before EUR 10M have been invested or after an investment in the range EUR 20-30M (figure below), possibly overlapping with a peak of M&A’s at the stage of Preclinical (11 of 43) and Phase II (23 of 43)!

The next peak in the figure below is after an investment of more than EUR 50M and again the majority stage is Phase II. Does this observation indicate that if you invest in interesting biology, and fail in Phase II, you will have the opportunity to invest more and with success try again in a new Phase II?

At Sunstone we think that is the case. We prefer opportunities with a broader investment thesis and we are hesitant about single assets with binary outcomes in Phase II.

When investing EUR 20-30M you should allow for the opportunity to learn something!

And as a curious side comment, it is interesting that only 6 out of the M&A’s were made after Phase I. Apparently human safety does not create sufficient value to cause an M&A 🙂

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...

Sunstone Life Science Ventures is looking for a Student Assistant

No longer accepting applications We are looking for a student to join our team for approximately 8 hours a week. As part of the team, you will play a pivotal role in the management of our deal flow, which lies in the order of 400-500 opportunities every year....

Sunstone announce new investment in immuno-oncology company STipe Therapeutics

Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.

Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...

5 latest articles

Who is in the driver’s seat of our industry?

A recent analysis from Pharma Intelligence | Informa 2021 highlights the current trends of pipeline products (top panel). We have subsequently surveyed Sunstone’s incoming deal flow for the same period and noted the correlation for the top 3 categories with oncology...

US IPO: Value recognition? Not really! Trading liquidity? Yes!

We previously looked at M&A of VC funded private and listed companies in the EU and US ( Listing EU companies in the US is perceived as more attractive or beneficial – but is it reflected in the numbers?  Recently, we decided to take a...

Why would you do a US IPO?

We recently compared EUR >50M M&A’s of VC funded EU and US drug developing companies and concluded that a substantial difference exists between the EU and US ( Previously we have also looked at EU M&A’s before or after an IPO....

M&A multiples in the US – should you go west?

Sunstone has previously investigated the return multiples of venture capital funded companies HQ’ed in Europe ( and concluded that when the total invested amount exceeds EUR 50M, the return multiple tends to stay below 5 in M&A transactions....

Best country for sourcing new deals?

Do you also in your mind have a priority list of destinations to visit once the world normalises and you can get back on a plane? If so, and if you are a Venture Capitalist, you may also be wondering which countries have been creating most Life Science M&A...

Why are we investing in Drug Development and hesitating with regards to Medical Devices or Diagnostics?

Part of the answer is obviously that our past experiences and successes fall within Drug Development – but also that both MedTech and Diagnostics seem to have a lower likelihood of getting to an exit once you have invested. Defining the field for Medical Devices and...